BREAKTHROUGH IMMUNOMODULATION THERAPY IN IDIOPATHIC PULMONARY FIBROSIS: A NARRATIVE LITERATURE REVIEW
MEDALION Journal: Medical Research, Nursing, Health and Midwife Participation · 06.01.2026 · 6 (4) · 504-508
DOI: 10.59733/medalion.v6i4.250 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEDALION Journal: Medical Research, Nursing, Health and Midwife Participation, online erschienen am 06.01.2026. Verfasst von Amiruddin und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Several antifibrotics such as pirfenidone and nintedanib have been shown to slow the decline in lung function but cannot stop the ongoing or existing fibrosis process. Recent evidence suggests that immune dysregulation, including macrophage activation and PD-L1 expression on fibroblasts, plays a key role in the pathogenesis of IPF, thus encouraging the emergence of potential immunomodulation therapies.
Methods
This paper attempts to review several English-language literature from 2015–2025 through PubMed, Scopus, and ClinicalTrials.gov. Articles relevant to immunotherapy, immunomodulators, or immune mechanisms in IPF were included, while non-scientific or non-immune-related publications were ignored.
Results
A total of 15 primary publications were identified. Immunotherapy approaches such as PD-L1 inhibition, Treg activation, and IL-4/IL-13 blockade have shown antifibrotic and immunoregulatory effects. New agents such as the TNIK inhibitor (ISM001-055), the peptide LTI-03, and CAR-Treg therapy have shown promising early results in translational models and early-phase clinical trials.
Conclusion
Immunotherapy has the potential to be a novel approach to IPF management by targeting the immune microenvironment. Further trials are needed to ensure safety and efficacy for long-term treatment.
Zitieren
APA
Amiruddin, & Amir, F. M. (2026). BREAKTHROUGH IMMUNOMODULATION THERAPY IN IDIOPATHIC PULMONARY FIBROSIS: A NARRATIVE LITERATURE REVIEW. MEDALION Journal: Medical Research, Nursing, Health and Midwife Participation, 6(4), 504-508. https://doi.org/10.59733/medalion.v6i4.250
Vancouver
Amiruddin, Amir FM. BREAKTHROUGH IMMUNOMODULATION THERAPY IN IDIOPATHIC PULMONARY FIBROSIS: A NARRATIVE LITERATURE REVIEW. MEDALION Journal: Medical Research, Nursing, Health and Midwife Participation. 2026;6(4):504-508. doi:10.59733/medalion.v6i4.250
BibTeX
@article{Amiruddin2026,
author = {Amiruddin and Amir, Faridj Maulana},
title = {BREAKTHROUGH IMMUNOMODULATION THERAPY IN IDIOPATHIC PULMONARY FIBROSIS: A NARRATIVE LITERATURE REVIEW},
journal = {MEDALION Journal: Medical Research, Nursing, Health and Midwife Participation},
year = {2026},
volume = {6},
number = {4},
pages = {504--508},
doi = {10.59733/medalion.v6i4.250}
}
EUVIMED